MedTech Dive January 10, 2024
The job cuts affect roles across corporate, sales and marketing, and operations.
Dive Brief:
- Spinal cord stimulation (SCS) specialist Nevro is laying off 63 people across corporate, sales and marketing, and operations to free up cash to invest in long-term growth and profitability.
- The restructuring, which will affect 5% of the workforce, is largely focused on internal roles, not customer-facing personnel in the field. Nevro expects to complete most of the layoffs by the end of the first quarter of 2023.
- Management disclosed the changes alongside preliminary results for the fourth quarter of 2022. Nevro is set to beat the analyst sales consensus estimate, driven by growth in painful diabetic neuropathy (PDN) and the stabilization of the core...
Today's Sponsors
Today's Sponsor
Topics: Medical Devices